Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 85%
filed 2026-07-13
Item 5.02
The filing discloses both a board resignation (Bill Beargie on July 7, 2026) and a board appointment (Rick Keyes on July 8, 2026). While both events are present, the substantive disclosure centers on the appointment of Rick Keyes as an independent director with detailed background on his qualifications, including his role as President and CEO of Meijer, Inc. since 2017, and his service on other public company boards. The appointment is the principal forward-looking action and is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-10
Item 5.02
O'Reilly appointed Colin Yankee as Executive Vice President and Chief Supply Chain Officer, effective July 13, 2026. While the disclosure includes compensatory details (base salary of $700,000, performance incentive target of 85%, stock option awards totaling $500,000 grant-date fair value plus annual grants), the principal disclosed action is the appointment of a named executive officer to a senior leadership position. This is a material executive appointment that would affect investor assessment of the company's leadership and operational strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-10
Item 5.02
Four independent directors—Garrett Curran, Alberto Alsina Gonzalez, Matthew Murphy, and Marc Spiegel—were appointed to the board of directors on July 9, 2026 in connection with the IPO, with assignments to the Audit and Compensation committees. This material governance event establishes the company's independent board oversight structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-10
Item 5.02
The filing discloses both the resignation of two directors (William M. Goodyear and Mark McGowan) and the appointment of Maria Veltre to the Board, effective immediately on July 10, 2026. While both events are disclosed, the principal action emphasized in the Item 5.02 structure and press release is the appointment of Veltre as a new director, making this an exec_appointment event. The departures are characterized as planned and non-contentious, and the Board reduction is a routine governance adjustment. Veltre's appointment to the Board of a NYSE-listed company is material to investors.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-10
The 6-K discloses the appointment of Wesley Chu as an independent director, chairman of the compensation committee, and member of the audit and nominating committees, effective July 10, 2026. While the filing also mentions the concurrent resignation of Qi Ding, the principal disclosed action is Chu's appointment to the Board with specific committee assignments and compensation. The appointment is material as it affects board composition and governance structure, particularly in the context of the Company's stated intention to increase U.S.-based board representation.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-10
The 6-K discloses the election of Mr. Alessandro de Castro Melo to the position of Chief Engineering, Technology and Innovation Officer by the Board of Directors on July 10, 2026. This is a material executive appointment to a named officer position, approved by the Board following recommendation by the People and Organization Committee, with a term extending to 2028.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-10
Item 7.01
The filing discloses the appointment of Jeff Hopmayer to MDWerks' Board of Directors, effective June 26, 2026. The press release (Exhibit 99.1) emphasizes Hopmayer's appointment as a pivotal addition to the board during a critical commercial inflection point, highlighting his experience in building and scaling businesses and his role in corporate strategy, partnerships, and M&A. This is a clear executive appointment event, material to investors assessing the company's leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-10
Item 5.02
The disclosure centers on the appointment of Matt Levine as Chief Legal Officer effective July 27, 2026, with detailed background on his prior roles at Clear Secure and Success Academy. While Erin Abrams's departure is also mentioned, the principal action disclosed is the appointment of a new CLO to fill this officer-level position. The appointment of a C-suite executive is material to investors assessing the company's leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-10
Item 5.02
The filing discloses the appointment of Joshua Chien as an independent director of the Board, effective July 8, 2026, upon recommendation from the Nominating and Corporate Governance Committee. While the Item 5.02 section also mentions compensatory arrangements (annual cash retainer of $60,000 and restricted share unit award of $170,000), the principal disclosed action is the appointment of a director to the Board. This is material as it affects the composition and governance of the company's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-10
Item 5.02
The filing discloses the appointment of two independent directors, Vivek Mohindra and Eiso Kant, to the Board of Directors of Axon Enterprise effective July 8, 2026, along with their committee assignments. While the disclosure also includes compensatory arrangements (RSU awards and cash retainers), the principal disclosed action centers on the appointment of these individuals to the Board and their committee roles, making exec_appointment the most salient classification. The material nature is clear given the addition of senior leadership to the Board.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-10
EX-99.1
The press release announces the appointment of Carl von Halem as Interim Chief Financial Officer of VERAXA Biotech AG, succeeding Torsten Bürgermeister. While the disclosure also references Bürgermeister's departure, the principal disclosed action is the appointment of a named executive to a C-suite role. The appointment of a CFO is material to investors as it affects the company's financial leadership and operational continuity, particularly given the company's recent NASDAQ listing and growth phase.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-10
Item 5.02
Neil Adler was appointed as Chief Financial Officer effective July 9, 2026, with an annual base salary of $200,000. The appointment follows the non-renewal of the employment agreement of departing CFO Neelam Patel, effective September 16, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
The filing discloses the appointment of three officers to SoCalGas: Karen L. Sedgwick as CEO and President (effective Q3 2026), Ross W. Turrini as Chief Operating Officer (effective August 10, 2026), and Elvia Lima Ortiz as Vice President, Chief Accounting Officer and Controller (effective July 10, 2026). While the section also includes a departure (Sara P. Mijares resigning as Chief Accounting Officer) and compensation details for the new appointees, the principal disclosed actions center on the three executive appointments, particularly the CEO appointment, which is material to investors assessing leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
Frank Scognamiglio was appointed as Corporate Vice President, Chief Accounting Officer, effective July 9, 2026, succeeding Christopher Caridi as the Company's principal accounting officer. While the disclosure includes compensatory details (base salary of $340,000, target bonus of 40%, and RSU grant of $100,000), the principal disclosed action is the appointment of an officer to a key financial leadership role. The appointment of a principal accounting officer is material to investors' assessment of financial reporting governance and internal controls.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
Central Plains Bancshares, Inc. appointed two individuals, Dannel R. Garness and Francis Younes, to the Boards of Directors of both Central Plains Bancshares, Inc. and Home Federal Savings and Loan Association of Grand Island on July 7, 2026. The appointment of Francis Younes followed an interview process initiated by activist shareholder pressure from the Stilwell Group.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
The company appointed Giorgio Matteo Tarditi as President and Chief Operating Officer, Louis Martin as Chief Commercial Officer, and Alfredo Luchini as Chief Financial Officer, effective August 3–10, 2026, representing a significant restructuring of senior leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
The filing discloses the Board's appointment of Justin C. Bird as Executive Vice President and Chief Financial Officer of Sempra, effective on or around the closing of the planned sale of Sempra Infrastructure Partners equity (Q3 2026). While the filing also mentions Karen L. Sedgwick's concurrent appointment as CEO and President of Southern California Gas Company, the principal disclosed action centers on Bird's appointment to the CFO role—a material executive position change at the parent company level. The appointment of a CFO with over two decades of leadership experience at Sempra is material to investors assessing the registrant's governance and financial leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 5.02
Kristina Campbell was appointed to the Board of Directors effective July 6, 2026, as an independent director and designated as Chair of the Audit Committee. Campbell brings extensive fintech and digital asset experience from her roles as CFO at Ripple Labs, PayNearMe, and Wrapbook, and is designated as an Audit Committee Financial Expert.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-09
Item 5.02
The filing discloses the appointment of Nancy Bowman, M.D., Ph.D., as Chief Regulatory Officer effective August 3, 2026, succeeding William Turner. While Turner's transition to Special Advisor represents a departure from his CRO role, the principal disclosed action centers on the appointment of a new CRO—a material executive officer position at a therapeutic company where regulatory affairs are critical to operations and strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-07-09
Item 5.02
FibroBiologics appointed Kathleen Rubins, Ph.D., a retired NASA astronaut and microbiologist, as a Class III director effective July 8, 2026, with assignment to the Audit, Compensation, and Governance committees. Dr. Rubins brings distinguished scientific credentials and has served on the company's Scientific Advisory Board since 2022.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 5.02
Paycom appointed two directors to its board effective July 8, 2026: Craig E. Boelte, former CFO (retired February 2025), and William Kerber, former CIO (departed 2017). Both individuals bring substantial company history and expertise to the board.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-09
EX-99.1
The press release announces the appointment of Ralph (Cody) Kittle to Telesat's Board of Directors as a nominee of MHR Fund Management LLC, succeeding Michael Targoff. This is a discrete governance event involving the appointment of a director to the board. While the release also acknowledges Targoff's departure after 19 years, the principal disclosed action is Kittle's appointment to the board, making this an exec_appointment event. Board composition changes at public companies are material to investors assessing governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 5.02
The disclosure centers on the appointment of Derek Rush as a director and member of the audit committee on July 2, 2026, increasing the Board to seven members. While the section also mentions an indemnification agreement, the principal disclosed action is the appointment of a person to a board role. This is material to investors as it affects board composition and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
On July 7, 2026, Bronwyn Barnes, Quinton Hennigh, Hugh Callaghan, and Michael Porter were appointed to the board of directors, with Barnes serving as Chairwoman and Porter chairing both the Audit and Compensation Committees.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-09
The 6-K discloses the appointment of two new independent directors effective July 9, 2026: Mr. King Fui Lee as an independent director and Audit Committee Chairman, and Mr. Ke Zhang as an independent director. While the filing also mentions the departure of two prior independent directors (Ms. Jie Jiao and Mr. Jingchuan Li), the principal disclosed action is the appointment of new board members with detailed biographical information, making this an exec_appointment event. Board composition changes affecting audit oversight are material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-09
Item 5.02
The filing discloses both a departure (Cory Nickel's termination as Senior Vice President and General Manager) and an appointment (John Jamieson's appointment to the same role, effective immediately on July 7, 2026). While both events occurred, the principal disclosed action centers on the appointment of Jamieson to a senior operational role with a salary increase from $193,000 to $205,000. The detailed biographical information and Board approval of compensation changes emphasize the appointment as the primary event. This is material as it involves a change in senior management responsible for operations.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-09
EX-99.1
The exhibit announces the appointment of Brian Hartzband as President of U.S. Operations, a named executive role. The disclosure emphasizes his responsibility for leading U.S. growth strategy, commercial operations, and market expansion—a material operational leadership position. The appointment is presented as a strategic milestone supporting the company's North American expansion and long-term growth execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 7.01
The filing discloses the Board's appointment of Alisa Bowen as Chief Executive Officer of FuboTV, effective July 10, 2026, succeeding co-founder David Gandler. While Gandler's departure is also mentioned, the principal disclosed action centers on the appointment of a new CEO—a veteran media executive with extensive experience at Disney, News Corporation, and other major media organizations. This is a material executive leadership transition at a public company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-09
Item 5.02
Haiyan Song was appointed as a new Class III director effective July 9, 2026, bringing cybersecurity and software expertise to strengthen the Board's capabilities. The appointment was accompanied by related board transitions including Greg Nixon's resignation as preferred stock director and Nathaniel Fick's transition from Class III to preferred stock director.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-09
GSK announced the appointment of Roy Jakobs as a Non-Executive Director effective 13 July 2026. The disclosure details his background as CEO of Royal Philips, his independence status, compensation terms (£122,258 annual fee), and share ownership requirements. This is a clear executive appointment to the Board, material to investors assessing governance and leadership composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-09
Item 5.02
David Kratochvil was appointed as Chief Executive Officer on July 2, 2026, following the resignation of Mike Schmidt. The appointment includes a new employment agreement with a base salary of $180,000 and 100,000 stock units.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 5.02
Enovix announced the appointment of Dr. Michael Vyvoda as Chief Operating Officer, effective July 29, 2026. The disclosure details his background, compensation package ($440,000 base salary plus 60% bonus target and $4.1 million in RSUs), and severance terms. While the filing includes compensatory arrangements, the principal disclosed action is the appointment of a named executive officer to a C-suite role, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 72%
filed 2026-07-09
Item 5.02
The disclosure centers on two executive transitions: David Pirman's promotion to Executive Vice President and Head of Discovery (a clear appointment to a senior role), and Bruce Car's transition from Chief Scientific Officer to Chief Innovation Officer (a role change with reduced compensation). While Car's departure from the CSO role is mentioned, the filing emphasizes the new appointments and organizational restructuring rather than focusing on departures. The promotion of Pirman to lead the internal drug-discovery organization and Car's continued service as an executive officer in a newly created role constitute material executive appointments that would affect investor assessment of the company's scientific leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-08
Item 5.02
Matthew Toboroff was appointed to the Board of Directors effective July 1, 2026, to fill a vacancy created by the death of Thom Kidrin. The disclosure centers on the appointment action itself. While the filing also mentions a related departure (Kidrin's passing), the principal disclosed action is Toboroff taking a director role. The appointment is material as it affects board composition and involves a related-party relationship (Toboroff's father is the Interim CEO and a Director).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-08
Item 5.02
Brad Martin was appointed as Executive Vice President and Chief Information Officer, a named executive officer role at the financial institution. The appointment was made in advance of Tammy Plummer's retirement to ensure a smooth leadership transition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-08
Item 5.02
Greg Lucas accepted an offer to serve as Vice President, Corporate Controller and Chief Accounting Officer, a principal accounting officer role, effective on or before August 10, 2026. While the disclosure includes compensatory details (base salary of $335,000, equity awards, and incentive plan eligibility), the principal disclosed action is the appointment of a named executive to a key accounting and financial reporting role, replacing Agnes Kamps as PAO. This is a material executive appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-08
Item 7.01
The filing announces the appointment of Dr. Lance Miller as Technical Advisor to Alaska Silver Corp., a position that brings significant technical expertise to the company's mineral exploration strategy. While the disclosure also mentions Darwin Green's departure from the Technical Committee, the principal action disclosed is the appointment of a new technical advisor with 35+ years of mining experience, making this an executive appointment event. The appointment is material to investors as it signals leadership changes in the company's technical direction for advancing the Illinois Creek project.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-08
Item 5.02
GMR Solutions appointed two independent directors, Dr. Amar Desai and Ellen Zane, to its Board of Directors effective July 1, 2026. Both appointees bring substantial healthcare leadership experience and will serve on key board committees.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-08
Item 5.02
The filing discloses a leadership transition where Kevin Buchel is appointed to Chief Executive Officer and President, with a salary increase to $900,000 and expanded management responsibilities. While Richard Soloway's role changes from CEO to Executive Chairman (a departure from the CEO position), the principal disclosed action centers on Buchel's appointment to the top executive role. The filing emphasizes Buchel's appointment and his qualifications for the position, making this primarily an appointment event rather than a departure, though both elements are present.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-08
Item 5.02
The filing discloses both departures and appointments effective July 3, 2026. Robert Szubanski resigned as Treasurer, Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer (retaining President role), and Varinia-Rebecca Koenig resigned as Secretary (retaining Board seat). Concurrently, Radek Chovanec was appointed to fill the vacated executive officer roles (Secretary, Treasurer, PEO, PFO, PAO) and elected as a Director. The principal disclosed action centers on the appointment of Chovanec to critical financial and operational leadership positions, making this an exec_appointment event. The material change in control of financial reporting and executive authority supports materiality.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-08
The 6-K discloses the appointment of Mr. Pang Peter Chun Ming as Chief Financial Officer effective July 8, 2026, following the resignation of Mr. Patrick Kwok Fai Lau on the same date. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite role (CFO), which is material to investors assessing management continuity and financial oversight. The detailed background of the incoming CFO (25+ years experience, CPA, CFA, prior CFO roles at public companies) supports materiality.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-08
Item 5.02
HF Sinclair Corp appointed Steven Ledbetter as President and Chief Operating Officer and Valerie Pompa as President, Growth, Technology and Transformation, effective July 6, 2026. Both executives were promoted from Executive Vice President roles, representing a material organizational restructuring at the C-suite level with Franklin Myers remaining CEO but ceding the President title.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-08
Item 5.02
The filing discloses the appointment of Jeremy Bender, Ph.D., M.B.A., as a Class II director to Aura Biosciences' Board, effective July 7, 2026. The Board unanimously appointed Dr. Bender to fill a newly created vacancy and assigned him to the Compensation Committee and Nominating and Corporate Governance Committee. This is a clear executive appointment event under Item 5.02, with material significance given Dr. Bender's substantial biotechnology leadership experience and the company's advancement toward regulatory approval of its lead candidate bel-sar.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-08
Item 5.02
Jane Pocock, currently CEO of Copart UK, has been appointed to the position of President of Copart, effective August 1, 2026, filling a previously vacant position. The company emphasized her track record leading the UK and Ireland business and her promotion to a global leadership position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-08
Item 5.02
The Board of Directors appointed Darcy Bajko to the position of Chief Commercial Officer effective July 31, 2026, with an annual salary of $315,000, bonus eligibility up to 30%, and a stock option grant of 150,000 shares.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-08
Item 5.02
On July 6, 2026, Clemence Rasigni and Christopher Kellen were appointed to the Board of Directors in connection with the IPO, with Ms. Rasigni designated as Audit Committee chair and Mr. Kellen as Compensation Committee chair.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-08
The filing discloses the appointment of Brent Morrison as an independent trustee of Power REIT, effective immediately on July 6, 2026. The Board explicitly states it appointed Morrison to serve until the next annual meeting and highlights his significant executive leadership experience at a publicly traded healthcare company, indicating the Board views his appointment as materially valuable to the Trust's governance and strategic objectives.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-08
The filing discloses the Board of Directors' approval on July 5, 2026, of Mr. John E. Driscoll's appointment as Co-Chief Operating Officer of Blue Chip Capital Group, Inc. The disclosure includes detailed biographical information, professional credentials (CFE, CIA), and extensive experience in corporate finance, accounting, and risk management. This is a clear executive appointment to a senior officer role, making it material to investors' assessment of the company's leadership and operational capacity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-08
Item 5.02
The filing discloses both the departure of Jeffrey Rona as Chief Business and Financial Officer and the appointment of Charles Carter as Chief Financial Officer, effective July 6, 2026. While both events occur, the principal disclosed action centers on Carter's appointment to the CFO role with detailed compensation arrangements (base salary of $460,000, 35% bonus target, 50,000 RSU grant), making exec_appointment the most salient classification. The departure is secondary context to the succession event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-08
Item 5.02
Michael Keogh's appointment as Chief Financial Officer effective August 5, 2026, is the principal disclosed action. While the filing also details his compensation package (base salary of $595,000, 85% target bonus, $2M RSU grant, and severance arrangements), the core event is the appointment of a named executive officer to a C-suite position. The disclosure emphasizes his extensive background at Ford, Apple, Stanley Black & Decker, and Intel, and his role is material to investors assessing the company's leadership and financial management capabilities.
View raw filing on EDGAR →